Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Rashmi Kumari

Moderna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?

Rapid tech advancements and soaring demand are positioning the biotech sector for rapid growth in the near term. Advances in genetic engineering, novel medicines, and greater investment in biotech companies and pharmaceutical alliances boost the sector.

So, quality biotech stock Acorda Therapeutics, Inc. (ACOR) could be worth buying. However, Moderna, Inc. (MRNA) is best avoided, considering its weak fundamentals.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.